A snapshot survey of biotech chiefs during the second quarter has shown that their confidence to be able to raise funds has doubled since Q1, but they are a…

Aurinia Pharmaceuticals has posted positive new data for its experimental drug voclosporin for active lupus nephritis--but 12 deaths in the study's…

Gene therapy biotech Spark Therapeutics has posted new long-term data for its Phase III trial of voretigene neparvovec, an experimental treatment for patients…

Investors knocked a few percentage points off Amarin’s share price after the firm added a second interim analysis to its Phase III cardiovascular disease trial…

The FDA will speed up its review of Shire’s experimental midstage fatty liver disease drug volixibat as the battle to be first to market in this emerging…

Sanofi and R&D partner Regeneron could have their experimental IL-6 inhibitor sarilumab approved in Europe by early 2017.

Adaptimmune has become one of the first companies to have a drug accepted into the EMA’s PRIME regulatory fast-track initiative.

Regulus Therapeutics saw its shares nosedive last month when the FDA put a clinical trial hold on its leading hep C candidate RG-101--but the company said this…